Related Experiment Video
Updated: Oct 7, 2025
A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022
Innovative therapeutic concepts of progressive multifocal leukoencephalopathy
Nora Möhn1, Lea Grote-Levi1, Franziska Hopfner1
1Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Abstract:
Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral disease of the brain-caused by human polyomavirus 2. It affects patients whose immune system is compromised by a corresponding underlying disease or by drugs. Patients with an underlying lymphoproliferative disease have the worst prognosis with a mortality rate of up to 90%. Several therapeutic strategies have been proposed but failed to show any benefit so far. Therefore, the primary therapeutic strategy aims to reconstitute the impaired immune system to generate an effective endogenous antiviral response. Recently, anti-PD-1 antibodies and application of allogeneic virus-specific T cells demonstrated promising effects on the outcome in individual PML patients. This article aims to provide a detailed overview of the literature with a focus on these two treatment approaches.
Insights
Progressive multifocal leukoencephalopathy (PML), a severe brain infection, has limited treatments. Reconstituting the immune system, particularly with anti-PD-1 antibodies or T cells, shows promise for PML patients.
Area of Science:
- Neurovirology
- Immunology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic brain infection caused by the human polyomavirus 2.
- PML primarily affects individuals with compromised immune systems due to underlying diseases or immunosuppressive therapies.
- Patients with lymphoproliferative disorders face a particularly grim prognosis, with mortality rates reaching up to 90%.
Purpose of the Study:
- To provide a comprehensive review of current therapeutic strategies for PML.
- To focus on emerging treatments, specifically anti-PD-1 antibodies and allogeneic virus-specific T cells.
- To assess the potential of immune reconstitution for managing PML.
Main Methods:
- Literature review focusing on PML treatment outcomes.
- Analysis of studies investigating immune-modulating therapies.
- Examination of case reports and clinical trials involving anti-PD-1 antibodies and T-cell therapies.
Main Results:
- Conventional therapeutic strategies for PML have largely been ineffective.
- Individual patient cases suggest promising outcomes with anti-PD-1 antibodies.
- Allogeneic virus-specific T cells have also shown potential benefits in treating PML.
Conclusions:
- Restoring immune function is the primary goal for effective PML treatment.
- Anti-PD-1 antibodies and virus-specific T cells represent novel therapeutic avenues.
- Further research is warranted to establish the efficacy and safety of these advanced treatments for PML.
Related Concept Videos
01:15Parkinson's Disease: Overview
01:22Alzheimer's Disease: Treatment
01:35Long-term Potentiation